|
Video: What is a Stock Split?
|
|
Zai Lab is a holding company. Through its subsidiaries, Co. is a commercial-stage biopharmaceutical company focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need in the China and global markets, including in the fields of oncology, infectious and autoimmune diseases. Co.'s products are: Niraparib, a selective oral, small molecule PARP 1/2 inhibitor with the potential to be a drug for treatment across multiple solid tumor types in China; and Optune, a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. According to our Zai Lab stock split history records, Zai Lab has had 0 splits. | |
|
Zai Lab (ZLAB) has 0 splits in our Zai Lab stock split history database.
Looking at the Zai Lab stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Zai Lab shares, starting with a $10,000 purchase of ZLAB, presented on a split-history-adjusted basis factoring in the complete Zai Lab stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/21/2017 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$31.11 |
|
End price/share: |
$15.66 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-49.66% |
|
Average Annual Total Return: |
-9.89% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,032.10 |
|
Years: |
6.59 |
|
|
|
|
|